)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Cardiff Oncology (CRDF) investor relations material
Cardiff Oncology Noble Capital Markets Emerging Growth Virtual Investor Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Noble Capital Markets Emerging Growth Virtual Investor Conference summary9 Oct, 2025
Lead asset overview and mechanism of action
Onvansertib is an oral, highly selective PLK1 inhibitor with 5,000-fold specificity over related kinases, enabling combination with chemotherapy due to low toxicity.
The drug’s unique mechanism allows it to target all RAS-mutant metastatic colorectal cancer (MCRC) subtypes, addressing a significant unmet need.
Preclinical studies show strong synergy between onvansertib and bevacizumab, inhibiting tumor angiogenesis and growth.
The mechanism involves shutting down the HIF1 alpha-driven hypoxic response, with two new U.S. patents extending protection to 2043.
Clinical trial data and program updates
The phase II CARDIFF-004 trial in first-line RAS-mutated MCRC showed a 49% confirmed objective response rate, nearly 20% higher than control.
Deep and durable responses were observed, including in difficult-to-treat patients, with some referred for curative surgery.
Early signs of improved progression-free survival (PFS) were noted, especially at the 30mg dose, with more mature data expected in Q1 2026.
Safety profile is favorable, with minimal additive toxicity and high patient compliance due to oral administration.
Phase III trial design is underway, aiming for accelerated and full approval endpoints based on objective response rate and PFS.
Strategic partnerships and financial position
Pfizer invested $15 million in 2021, holds over 3%, and provides trial support via Pfizer Ignite, but does not own rights to onvansertib.
The company retains full control of the asset and expects to be funded into early 2027, with $71 million in cash as of June 2025.
Next major clinical update from the 004 trial is expected in Q1 2026.
What is the competitive landscape for onvansertib?
What durability data is expected in Q1 2026?
Describe onvansertib's novel angiogenesis MOA.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cardiff Oncology earnings date
Q3 20256 Nov, 2025
Next Cardiff Oncology earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Cardiff Oncology Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for various cancers. The company's primary approach involves leveraging PLK1 (Polo-like Kinase 1) inhibition to create novel cancer treatments. Their flagship product, onvansertib, is an oral selective PLK1 inhibitor currently being evaluated in combination with standard-of-care therapeutics across several clinical programs. These include treatments for KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage